For years, the conversation around humanity’s future in space has revolved around one destination: Mars. Much of that discussion has centered on Elon Musk and SpaceX, whose long-term vision is nothing less than building a self-sustaining city on the Red Planet. But before NASA attempts a journey that spans more than 140 million miles, it ... NASA Crowns New Leader in Race to Colonize the Moon. It’...
For years, the conversation around humanity’s future in space has revolved around one destination: Mars. Much of that discussion has centered on Elon Musk and SpaceX, whose long-term vision is nothing less than building a self-sustaining city on the Red Planet. But before NASA attempts a journey that spans more than 140 million miles, it ... NASA Crowns New Leader in Race to Colonize the Moon. It’s Not SpaceX.
A renewed, though relatively limited, exchange of military action between the United States and Iran has tempered optimism surrounding a swift diplomatic breakthrough. Nevertheless, many market participants continue to believe that a longer-term agreement remains achievable.
A renewed, though relatively limited, exchange of military action between the United States and Iran has tempered optimism surrounding a swift diplomatic breakthrough. Nevertheless, many market participants continue to believe that a longer-term agreement remains achievable.
Hormel Foods beat Q2 fiscal 2026 EPS estimates with 40 cents adjusted, up 14% year-over-year, as all three segments posted profit growth and organic sales rose 3%.
Hormel Foods beat Q2 fiscal 2026 EPS estimates with 40 cents adjusted, up 14% year-over-year, as all three segments posted profit growth and organic sales rose 3%.
Actively managed funds have higher costs than their passive peers in most cases, but may also come with the potential for enhanced returns, dividends, and more.
Actively managed funds have higher costs than their passive peers in most cases, but may also come with the potential for enhanced returns, dividends, and more.
Akeso, whose drug ivonescimab was hailed as biotech’s “DeepSeek moment” amid US competition last year, announced better-than-expected clinical results showing it can treat a type of lung cancer commonly found in smokers, potentially expanding its approved uses. Analysts suggest it could become a backbone therapy in the US$20 billion global non-small cell lung cancer market and have revised their t...
Akeso, whose drug ivonescimab was hailed as biotech’s “DeepSeek moment” amid US competition last year, announced better-than-expected clinical results showing it can treat a type of lung cancer commonly found in smokers, potentially expanding its approved uses. Analysts suggest it could become a backbone therapy in the US$20 billion global non-small cell lung cancer market and have revised their target prices upwards. The drug’s phase three trial found that ivonescimab reduced the risk of death...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.